In contrast to experimental studies, clinical data on the role of these proteins is less clear, although some studies for other tumor entities indeed indicated that ABC-transporters negatively influence clinical response or survival of patients suffering from tumors of the lung [9]–[10], the breast [11]–[12], the liver [13], or the kidney [14]. This evidence concerns the gene ABCG2 and neoplasm.